ReviewJournal of medical case reports2026
Sertraline-induced bruxism: a case report and review of the literature.
Review in Journal of medical case reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundBruxism, characterized by involuntary teeth grinding and jaw clenching, is an uncommon but likely underrecognized adverse effect of selective serotonin reuptake inhibitors. Sertraline is generally considered safe for anxiety disorders, yet individual pharmacogenetic variability in CYP2C19 and CYP2D6 may predispose to serotonergic-dopaminergic imbalance and movement disorders. CASE PRESENTATION: We describe a 42-year-old Indian woman with generalized anxiety disorder (baseline HAM-A 32) who was started on sertraline 25 mg/day and titrated to 50 mg/day on day 5. About 10 days after initiation, she developed severe bruxism with jaw pain despite clear clinical improvement in anxiety (HAM-A 12). The patient's bruxism was predominantly awake bruxism, characterized by daytime jaw clenching and teeth grinding during stressful periods. A dental evaluation ruled out occlusal abnormalities, temporomandibular joint inflammation, and tooth wear, and a mouthguard was deemed ineffective. A dechallenge with tapering and discontinuation of sertraline led to the resolution of jaw pain and reduction in bruxism. Pharmacogenetic testing showed CYP2C19*2/*17 (intermediate metabolizer) and CYP2D6*2/*41 (normal metabolizer). On the basis of Clinical Pharmacogenetics Implementation Consortium recommendations, she was switched to venlafaxine 37.5 mg twice daily, which achieved anxiety remission (HAM-A 6), but mild teeth grinding persisted. Adjunctive buspirone 5 mg/day led to complete resolution within 4 weeks. The temporal relationship, improvement on withdrawal, and a Naranjo score of 9 supported a probable sertraline-induced bruxism.
conclusionThis case highlights sertraline-induced bruxism as a less commonly recognized but clinically significant adverse drug reaction. It shows that pharmacogenetic-guided antidepressant selection, combined with buspirone augmentation, can optimize management in selective serotonin reuptake inhibitor-associated bruxism. Clinicians should screen for bruxism during early sertraline titration, especially in patients with CYP2C19-reduced function alleles.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.